KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Receivables (2016 - 2026)

Idexx Laboratories has reported Receivables over the past 17 years, most recently at $865.1 million for Q4 2025.

  • For Q4 2025, Receivables rose 20.17% year-over-year to $865.1 million; the TTM value through Dec 2025 reached $865.1 million, up 20.17%, while the annual FY2025 figure was $865.1 million, 20.17% up from the prior year.
  • Receivables for Q4 2025 was $865.1 million at Idexx Laboratories, up from $855.6 million in the prior quarter.
  • Over five years, Receivables peaked at $865.1 million in Q4 2025 and troughed at $504.4 million in Q1 2021.
  • A 5-year average of $669.2 million and a median of $666.3 million in 2023 define the central range for Receivables.
  • Biggest five-year swings in Receivables: soared 30.04% in 2021 and later increased 5.78% in 2024.
  • Year by year, Receivables stood at $528.2 million in 2021, then increased by 11.96% to $591.4 million in 2022, then increased by 15.07% to $680.5 million in 2023, then increased by 5.78% to $719.9 million in 2024, then increased by 20.17% to $865.1 million in 2025.
  • Business Quant data shows Receivables for IDXX at $865.1 million in Q4 2025, $855.6 million in Q3 2025, and $835.4 million in Q2 2025.